Pulmonary Embolism and COVID-19

• Conditions: Covid-19; Pulmonary Embolism
• Interventions: Other: intensive care unit admission ratio

• Registration Number: NCT04590378
• Lead Sponsor: Uşak University

Brief Summary

The charts of patients who developed pulmonary embolism in the course of COVID-19 will be evaluated, retrospectively. Clinical features and laboratory data will be analyzed.

Detailed Description

Patients with COVID-19 infection will be evaluated retrospectively. Demographic data, clinical and laboratory findings will be recorded. Findings of patients with pulmonary embolism and withour pulmonary embolism will be compared.

Study Timeline

• Study Start: 2020-03-01
• Study First Submitted: 2020-10-14
• Study First Submitted QC: 2020-10-15
• Study First Posted: 2020-10-19
• Status Verified: 2021-05
• Last Update Submitted: 2021-05-01
• Last Update Posted: 2021-05-04
• Primary Completion: 2021-06-01
• Study Completion: 2021-12-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 600

Inclusion Criteria

• All patients with positive RT-PCR for COVID-19

Exclusion Criteria

• All patients with negative RT-PCR for COVID-19

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Covid-19 Patients with Pulmonary embolism	intensive care unit admission ratio	Clinically demonstared cases infected with COVID-19 who developed pulmonary embolism.
Covid-19 Patients without Pulmonary embolism	intensive care unit admission ratio	Clinically demonstared cases infected with COVID-19 who did not develop pulmonary embolism.

Primary Outcome Measures

Name	Time	Method
pulmonary embolism	1 year	development of pulmonary embolism

Secondary Outcome Measures

Name	Time	Method
mortality	1 year	mortality rate due to pulmonary embolism
Intensive care unit	1 year	need for admission to intensive care unit

Trial Locations

Locations (1)

Uşak University; 🇹🇷 Usak, Turkey